



Date: 13<sup>th</sup> April, 2026

|   |  |
|---|--|
| To<br>The Listing Department<br><b>National Stock Exchange of India Limited</b><br>Exchange Plaza,<br>Bandra – Kurla Complex<br>Bandra (East)<br>Mumbai – 400 051<br><b>Stock Code : INDOCO</b> | To<br>The Listing Department<br><b>Bombay Stock Exchange Limited</b><br>Floor 25, P. J. Towers,<br>Dalal Street,<br>Mumbai – 400 001<br><b>Stock Code : 532612</b> |
|---|--|

Dear Sir/Madam,

**Subject: Update on the Company's testing facility at Chhatrapati Sambaji Nagar (Aurangabad)**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the U.S. Food and Drug Administration (U.S. FDA) completed Pre-Approval Inspection at the Company's testing facility in Chhatrapati Sambaji Nagar (Aurangabad).

The inspection was carried out from April 08, 2026 to April 10, 2026, and concluded with zero form 483 observations.

Please take the above information on record.

**Thanking you,  
Yours faithfully,  
For Indoco Remedies Limited**



**Ramanathan Hariharan  
Company Secretary & Head Legal**